Evidence map›Paper›PMID 27748010›Full record

ArticlePediatric blood & cancer2017

Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia.

Samara L Potter, Rajkumar Venkatramani, Scott Wenderfer, Brett H Graham, Sanjeev A Vasudevan, Andrew Sher, Hao Wu, David A Wheeler, Yaping Yang, Christine M Eng and 4 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Pediatric blood & cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Frontiers in physiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Samara L PotterDepartment of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
Rajkumar VenkatramaniDepartment of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
Scott WenderferDepartment of Pediatric, Division of Nephrology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
Brett H GrahamDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Sanjeev A VasudevanDepartment of Surgery, Texas Children's Hospital, Houston, Texas.
Andrew SherDepartment of Radiology, Baylor College of Medicine, Houston, Texas.
Hao WuDepartment of Pathology, Texas Children's Hospital, Houston, Texas.
David A WheelerThe Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Yaping YangDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Christine M EngDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Richard A GibbsDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Angshumoy RoyDepartment of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
Sharon E PlonDepartment of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
D Williams ParsonsDepartment of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
Baylor College of Medicine · USBaylor Genetics · USChildren's Cancer Center · USBoston Children's Hospital · US

Funding

Measuring Perceptions of Utility of Clinical Genome Sequencing: Instrument Testing and ValidationU01HG006485 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI MCGUIRE, AMY L, PARSONS, DONALD W. · 2012 to 2021
$22.1M
PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAMK12CA090433 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CARL E ALLEN, Donald W. Parsons · 2002 to 2026
$18.5M
NCI NIH HHS K12 CA090433NHGRI NIH HHS U01 HG006485
6 · The paper itself

Abstract

Pediatric renal cell carcinoma (RCC) is a rare cancer that can be associated with inherited diseases including tuberous sclerosis complex (TSC) caused by germline mutations in TSC1 or TSC2. Somatic mutations in TSC1 and TSC2 have also been reported in adult RCC, which predict response to mTOR inhibitors. Here, we present the first case of RCC in a child with methylmalonic acidemia (MMA). Clinical whole exome sequencing of blood and tumor samples confirmed the diagnosis of MMA and revealed two somatic inactivating mutations in TSC2, suggesting the potential consideration of an mTOR inhibitor in the event of tumor recurrence.

Indexed as

Amino Acid Metabolism, Inborn ErrorsAntineoplastic AgentsCarcinoma, Renal CellChildEverolimusFemaleHumansKidney NeoplasmsSirolimusTOR Serine-Threonine KinasesTuberous Sclerosis Complex 2 ProteinTumor Suppressor ProteinsAntineoplastic AgentsEverolimusMTOR protein, humanSirolimustemsirolimusTOR Serine-Threonine KinasesTSC2 protein, humanTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteinsmethylmalonic acidemiarenal cell carcinomaTSC2

Identifiers

PMID27748010
PMCPMC5469213
OpenAlexW2534684077

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.